Vascular Surgery Research 1.888.287.1082 Text Size
Connecting with Us

Connecting with Vascular Surgery

The vascular surgeons in the University of Michigan Cardiovascular Center are known worldwide for their excellent clinical, educational and research programs. Every year they impact more than 3,000 lives by providing the highest quality family-centered care for individuals with a variety of vascular conditions. While these valiant efforts are making a remarkable difference for today's patients, there are still many more advancements to be achieved to treat the patients of tomorrow.

More and more we depend on outside help to move these programs forward. With your contribution, we will continue the fight to diagnosis and treat aortic, carotid, peripheral arterial and venous diseases while improving patient care and saving lives.

Make a gift today online or via a printable mail-in form (PDF).

Translating Research to Care

Our patients have access to the most up-to-date treatments and medications available. This is in no small part due to the very active research environment fostered at the University of Michigan. New research is essential in order for us to improve the care that we currently give. It also allows us to be a valuable partner for referring physicians when patients may require specialized care for venous disease.

Some of our current research efforts include:

  • Researching P-selectin inhibitors to prevent clots from forming. Our team received a five-year, $3.7 million dollar grant to pursue this research with Harvard University and the biopharmaceutical company Archemix Corp.
  • A multi-center study called ATTRACT, which stands for Acute Venous Thrombosis; Thrombus Removal with Adjunctive Catheter-Directed Thombolysis.
  • A Program Project Grant for which the core is Novel Targets in Thrombosis and Atherosclerosis.
  • NIH grant examining gender differences in abdominal aortic aneurysms
  • NIH study for Vein Wall Remodeling after Deep Vein Thrombosis
  • Participation in the Michigan Anticoagulation Quality Improvement Initiative (MAQI2), a Blue Cross/Blue Shield of Michigan-sponsored study of how anticoagulation therapy is delivered, and how to improve anticoagulation care.
  • A study where results showed that DVI is not a barrier to the safe and effective performance of EVA for the GSV
  • A large-scale study where U-M is one of about 50 participating institutions nationwide that compares standard treatment - blood thinners, compression stockings and reliance on the body's own methods of breaking down clots - with newer, catheter-based methods of directly dissolving and removing the clot. Patients will be evaluated at the end of the study on both medical and quality-of-life outcomes.

To learn more about giving opportunities in Vascular Surgery, please contact the Surgery Development Office at 800-588-5844. Or make a gift today online or via a printable mail-in form (PDF).